Opening Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
- Length
- 56 min
- Level
- Undergraduate
- Recorded
- University of Louisville2026
Chapter 1 of 9: Before the lecture
Factor XI inhibition represents an emerging pharmacological approach for secondary stroke prevention that uncouples thrombosis from hemostasis. The physiological pathways of hemostasis and thrombosis are contrasted to explain why factor XIa antagonists reduce recurrent ischemic stroke without increasing major bleeding complications. Clinical trial data from the Oceanic stroke study using asundexian demonstrate a significant reduction in ischemic stroke events relative to placebo. Subgroup analyses show consistent efficacy across various stroke etiologies and baseline severities. The lecture also reviews the current limitations of dual antiplatelet therapy and direct oral anticoagulants in non-cardioembolic stroke management.

Your comment is kept while you sign up.Sign in
Weighs the Oceanic stroke trial, where asundexian cut recurrent ischemic stroke without added major bleeding.
Factor XI inhibition represents an emerging pharmacological approach for secondary stroke prevention that uncouples thrombosis from hemostasis. The physiological pathways of hemostasis and thrombosis are contrasted to explain why factor XIa antagonists reduce recurrent ischemic stroke without increasing major bleeding complications. Clinical trial data from the Oceanic stroke study using asundexian demonstrate a significant reduction in ischemic stroke events relative to placebo. Subgroup analyses show consistent efficacy across various stroke etiologies and baseline severities. The lecture also reviews the current limitations of dual antiplatelet therapy and direct oral anticoagulants in non-cardioembolic stroke management.
Lancet Neurol. 2025 Feb;20(2):132-144
Europace. 2024;26(7):euae195
Front Public Health. 2023;15:1569179
JAMA Intern Med. 2022;182(5):559-564.
COMPASS Trial
Sharma M, et al. Eur Stroke J
Factor XI deficiency and epidemiology studies
FXIa Inhibitors and Therapeutic Options
N Engl J Med 2026;394(15):1467-1479
Lancet Neurol. 2024;23(1):46-59
Lancet. 2022;400(10357):997-1007
Sharma et al. N Engl J Med. 2026;394(15):1467-1479.
This lecture
Talk 2 of 115 of UofL Neurology Grand Rounds.
Choose a node to see how it connects to this lecture. What comes before is on the leftat the top. What comes after is on the rightat the bottom. The ring is what it teaches. People and places are above. Other lectures and books are below.
Press a chosen node again to open it.